Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.

Hay MP, Shin HN, Wong WW, Sahimi WW, Vaz ATD, Yadav P, Anderson RF, Hicks KO, Wilson WR.

Molecules. 2019 Jul 10;24(14). pii: E2524. doi: 10.3390/molecules24142524.

2.

Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.

Mao X, McManaway S, Jaiswal JK, Hong CR, Wilson WR, Hicks KO.

Cancer Biol Ther. 2019;20(9):1258-1269. doi: 10.1080/15384047.2019.1617570. Epub 2019 May 26.

PMID:
31131698
3.
4.

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.

Mao X, McManaway S, Jaiswal JK, Patel PB, Wilson WR, Hicks KO, Bogle G.

PLoS Comput Biol. 2018 Oct 24;14(10):e1006469. doi: 10.1371/journal.pcbi.1006469. eCollection 2018 Oct.

5.

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.

Hong CR, Bogle G, Wang J, Patel K, Pruijn FB, Wilson WR, Hicks KO.

Front Pharmacol. 2018 Sep 18;9:1013. doi: 10.3389/fphar.2018.01013. eCollection 2018.

6.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW.

JCI Insight. 2018 Aug 23;3(16). pii: 122204. doi: 10.1172/jci.insight.122204. eCollection 2018 Aug 23.

7.

Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.

Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR.

Biochem Pharmacol. 2018 Oct;156:265-280. doi: 10.1016/j.bcp.2018.08.027. Epub 2018 Aug 19.

PMID:
30134191
8.

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.

Bonnet M, Hong CR, Wong WW, Liew LP, Shome A, Wang J, Gu Y, Stevenson RJ, Qi W, Anderson RF, Pruijn FB, Wilson WR, Jamieson SMF, Hicks KO, Hay MP.

J Med Chem. 2018 Feb 8;61(3):1241-1254. doi: 10.1021/acs.jmedchem.7b01678. Epub 2018 Jan 11.

PMID:
29253343
9.

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice.

Gu Y, Chang TT, Wang J, Jaiswal JK, Edwards D, Downes NJ, Liyanage HDS, Lynch CRH, Pruijn FB, Hickey AJR, Hay MP, Wilson WR, Hicks KO.

Front Pharmacol. 2017 Aug 11;8:531. doi: 10.3389/fphar.2017.00531. eCollection 2017.

10.

Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice.

Campbell EJ, Vissers MCM, Wohlrab C, Hicks KO, Strother RM, Bozonet SM, Robinson BA, Dachs GU.

Free Radic Biol Med. 2016 Oct;99:451-462. doi: 10.1016/j.freeradbiomed.2016.08.027. Epub 2016 Aug 24.

PMID:
27567539
11.

Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.

Hong CR, Wang J, Hicks KO, Hay MP.

Adv Exp Med Biol. 2016;899:269-90. doi: 10.1007/978-3-319-26666-4_16.

PMID:
27325273
12.

Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue.

Kuiper C, Vissers MC, Hicks KO.

Free Radic Biol Med. 2014 Dec;77:340-52. doi: 10.1016/j.freeradbiomed.2014.09.023. Epub 2014 Sep 30.

PMID:
25277418
13.

Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.

Gu Y, Jaiswal JK, Wang J, Hicks KO, Hay MP, Wilson WR.

J Pharm Sci. 2014 Nov;103(11):3464-3472. doi: 10.1002/jps.24099. Epub 2014 Sep 11.

PMID:
25212501
14.

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.

Bonnet M, Hong CR, Gu Y, Anderson RF, Wilson WR, Pruijn FB, Wang J, Hicks KO, Hay MP.

Bioorg Med Chem. 2014 Apr 1;22(7):2123-32. doi: 10.1016/j.bmc.2014.02.039. Epub 2014 Mar 3.

PMID:
24650701
15.

Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Foehrenbacher A, Secomb TW, Wilson WR, Hicks KO.

Front Oncol. 2013 Dec 27;3:314. doi: 10.3389/fonc.2013.00314. Review.

16.

Hypoxia-directed drug strategies to target the tumor microenvironment.

Hay MP, Hicks KO, Wang J.

Adv Exp Med Biol. 2014;772:111-45. doi: 10.1007/978-1-4614-5915-6_6. Review.

PMID:
24272357
17.

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

Foehrenbacher A, Patel K, Abbattista MR, Guise CP, Secomb TW, Wilson WR, Hicks KO.

Front Oncol. 2013 Oct 7;3:263. doi: 10.3389/fonc.2013.00263. eCollection 2013.

18.

The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.

Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, Wilson WR.

Clin Cancer Res. 2012 Mar 15;18(6):1684-95. doi: 10.1158/1078-0432.CCR-11-2296. Epub 2011 Dec 13.

19.

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.

Clin Cancer Res. 2010 Oct 15;16(20):4946-57. doi: 10.1158/1078-0432.CCR-10-1439. Epub 2010 Aug 20.

20.

A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.

Patel K, Choy SS, Hicks KO, Melink TJ, Holford NH, Wilson WR.

Cancer Chemother Pharmacol. 2011 May;67(5):1145-55. doi: 10.1007/s00280-010-1412-z. Epub 2010 Aug 4.

PMID:
20683596
21.

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.

Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, Anderson RF, Shinde SS, Wilson WR, Denny WA.

J Med Chem. 2008 Nov 13;51(21):6853-65. doi: 10.1021/jm800967h. Epub 2008 Oct 11.

22.

Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.

Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, Shinde SS, Phillips V, Denny WA, Wilson WR.

J Med Chem. 2007 Dec 27;50(26):6654-64. Epub 2007 Dec 6.

PMID:
18052317
23.

Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.

Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA.

J Med Chem. 2007 Dec 13;50(25):6392-404. Epub 2007 Nov 15.

PMID:
18001018
24.

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.

Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):560-71.

PMID:
17869669
25.

Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.

Patel K, Lewiston D, Gu Y, Hicks KO, Wilson WR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):302-11. Epub 2007 Jul 6.

PMID:
17644498
26.

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.

Clin Cancer Res. 2007 Jul 1;13(13):3922-32.

27.

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.

Radiat Res. 2007 Jun;167(6):625-36.

PMID:
17523848
28.

Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.

Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, Denny WA, Dewhirst MW, Wilson WR.

J Natl Cancer Inst. 2006 Aug 16;98(16):1118-28.

PMID:
16912264
29.

Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.

Pruijn FB, Sturman JR, Liyanage HD, Hicks KO, Hay MP, Wilson WR.

J Med Chem. 2005 Feb 24;48(4):1079-87.

PMID:
15715475
30.
31.

In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors.

Wilson WR, Pullen SM, Hogg A, Hobbs SM, Pruijn FB, Hicks KO.

Methods Mol Med. 2004;90:403-31. No abstract available.

PMID:
14657576
32.
33.

Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA.

Cancer Res. 2002 Mar 1;62(5):1425-32.

35.

Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.

Siim BG, Hicks KO, Pullen SM, van Zijl PL, Denny WA, Wilson WR.

Biochem Pharmacol. 2000 Oct 1;60(7):969-78.

PMID:
10974206
36.

Measurement of extravascular drug diffusion in multicellular layers.

Wilson WR, Hicks KO.

Br J Cancer. 1999 Mar;79(9-10):1623-6. No abstract available.

PMID:
10188919
37.

Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model.

Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR.

Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):641-9.

PMID:
9806526
38.

An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours.

Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR.

Br J Cancer. 1997;76(7):894-903.

39.

Multicellular membranes as an in vitro model for extravascular diffusion in tumours.

Cowan DS, Hicks KO, Wilson WR.

Br J Cancer Suppl. 1996 Jul;27:S28-31.

40.

A simple method for estimating tubular and net glomerular capillary pressures in the isolated perfused kidney.

Bullivant M, Hicks KO, Smaill BH.

Pflugers Arch. 1981 Mar;389(3):251-5.

PMID:
7195010

Supplemental Content

Loading ...
Support Center